Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. is a U.S.-based biopharmaceutical company focused on developing therapies for central nervous system disorders. Its pipeline includes product candidates for epilepsy, essential tremor, and other neurological diseases, with development conducted through a virtual model that relies on external research, clinical, and manufacturing partners.

−100,0 %

10.22

10.22

— Praxis Precision Medicines, Inc.
%
Neurology drug candidates70% Clinical-stage therapies targeting movement disorders and epilepsy-related CNS conditions.
Preclinical pipeline20% Earlier-stage antisense programs aimed at genetically defined neurological disorders.
Collaboration revenue10% Research and development collaboration income from partnered programs.

Praxis does not yet sell commercial products; its near-term counterparties are regulators, clinical investigators,...

  • Neurology prescribersprimary

    Specialists who would prescribe ulixacaltamide, relutrigine, or vormatrigine if approved, based on efficacy and safety in difficult-to-treat CNS disorders.

  • Third-party payorsprimary

    Commercial insurers and government programs that would determine coverage and reimbursement for approved therapies.

  • Clinical development partnersprimary

    CROs, CDMOs, and consultants that provide trial execution, manufacturing, and regulatory support.

  • Patients with rare or refractory neurological diseaseprimary

    Patients with essential tremor, epilepsy, or genetically defined neurodevelopmental disorders who are the end beneficiaries of the pipeline.

Praxis is headquartered in the United States and conducts most of its development and corporate activity from there...

  • •Headquartered and operated in the United States
  • •Clinical and regulatory work is centered on U.S. programs
  • •Future commercialization would likely begin in major U.S. markets
  • •European pricing and reimbursement rules could affect expansion
  • •Manufacturing is outsourced to third-party partners, not owned sites

Praxis is advancing a pipeline of precision medicines for neurological disease, with emphasis on late-stage clinical...

01
Advance late-stage neurology programsshort-term

Clinical and regulatory progress is the main path to future product revenue.

02
Build commercialization readinessshort-term

Approved products will require sales, marketing, distribution, and payer access capabilities.

03
Expand the precision neurology pipelinemedium-term

A broader pipeline can diversify scientific risk and create follow-on value.

04
Maintain IP and external development modellong-term

The company depends on proprietary science and outsourced execution to scale efficiently.

Praxis faces the core risks of a clinical-stage biopharmaceutical company: clinical failure, regulatory setbacks, and...

critical

Clinical development failure

The company has no approved products and depends on successful trial outcomes to create value.

Scope
Ulixacaltamide, relutrigine, vormatrigine, elsunersen
Materiality
high
high

Regulatory approval risk

Even positive data may not translate into FDA approval or a timely review process.

Scope
NDA and registrational-stage programs
Materiality
high
high

Manufacturing and supply chain dependence

All clinical and future commercial supply is outsourced to third-party CDMOs.

Scope
Drug substance, fill-finish, packaging, distribution
Materiality
high
high

Commercial adoption and reimbursement

Prescribers and payors may be slow to adopt new CNS therapies, especially for unfamiliar mechanisms.

Scope
Essential tremor and epilepsy markets
Materiality
high
high

Capital needs

The company expects to fund operations through external capital until product sales exist, if ever.

Scope
R&D, trials, commercialization buildout
Materiality
high
Research and development accruals
Can materially affect quarterly operating expense and liabilities
Collaboration revenue recognition
Can create uneven non-product revenue
Vendor termination obligations
Creates contingent commitments and cash flow risk
IP and licensing arrangements
Affects expense timing and future obligations

PRECIGEN, INC.

PGEN · Pharmaceutical Preparations

PRECISION BIOSCIENCES INC

DTIL · Biological Products, (No Diagnostic Substances)

Revolution Medicines, Inc.

RVMD · Biological Products, (No Diagnostic Substances)

Tango Therapeutics, Inc.

TNGX · Pharmaceutical Preparations

Maze Therapeutics, Inc.

MAZE · Biological Products, (No Diagnostic Substances)

INOVIO PHARMACEUTICALS, INC.

INO · Pharmaceutical Preparations

: 29.4.2026